Comparison of the effect of haloperidol and quetiapine in the prevention of delirium in patients with end-stage cancer candidates receiving palliative care at home

Evaluation and comparison of the effect of haloperidol and quetiapine in the prevention of delirium in patients with end-stage cancer candidates receiving palliative care at home

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201205049612N1

Enrollment

Registered

2021-01-16

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium. Delirium due to known physiological condition

Interventions

Intervention 1: Intervention group: Haloperidol receptor (1 mg daily / divided into 2 doses). Intervention 2: Intervention group: Quetiapine receptor (25 mg daily / divided into 2 doses).

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of any type of end-stage cancer in the patient by the oncologist (discontinuation of therapeutic treatment with a prognosis of less than 6 months) Conscious consent of the patient or his family to participate in the study

Exclusion criteria

Exclusion criteria: Existence of major neurocagnetic disorder Existence of delirium disorder according to DSM-V criteria by a psychiatric assistant and obtaining a score less than 5 in the ICDSC questionnaire Any contraindications to the use of antipsychotic drugs

Design outcomes

Primary

Measure	Time frame
Delirium prevention. Timepoint: 12 weeks after starting the drug. Method of measurement: ICDSC questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammadreza Sharbafchi

Esfahan University of Medical Sciences

nour@mui.ac.ir+98 31 3222 2127

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026